Table 5 AEs during 180-day follow-up
Characteristic | Omeprazole group (n = 303) | Pantoprazole group (n = 304) | P value |
|---|---|---|---|
Stent thrombosis [n (%)] | 0 | 0 | — |
MACEs [n (%)] | 8 (2.6) | 7 (2.3) | 0.80 |
Cardiac death | 1 (0.3) | 0 | 0.50 |
Myocardial infarction | 0 | 0 | — |
Ischemic symptoms driven target vessel revascularization | 3 (1.0) | 1 (0.3) | 0.37 |
Non-target vessel revascularization | 6 (2.0) | 6 (2.0) | 1.00 |
Recurrent angina [n (%)] | 30 (9.9) | 24 (7.9) | 0.40 |
All-cause death [n (%)] | 1 (0.3)a | 1 (0.3)b | 1.00 |
TIMI bleeding evens [n (%)] | 15 (5.0) | 19 (6.3) | 0.60 |
Major | 0 | 1 (0.3) | 1.00 |
Moderate | 0 | 3 (1.0) | 0.25 |
Minor | 16 (5.3) | 14 (4.6) | 0.71 |
Stroke [n (%)] | 1 (0.3) | 0 | 0.50 |
Adverse drug reactions [n (%)] | 17 (5.6) | 19 (6.3) | 0.86 |
AEs [n (%)] | 50 (16.5) | 44 (14.5) | 0.50 |